Imaging Abdominal Aortic Aneurysms with 64Cu-DOTA-ECL1i
This research study is looking at how a special imaging drug called 64Cu-DOTA-ECL1i can help doctors see inflammation in abdominal aortic aneurysms (AAA). An AAA is a weakening and bulging in the main artery that carries blood from your heart to your body. The drug is used with an imaging test called a PET/CT scan. Researchers want to see if 64Cu-DOTA-ECL1i can create clear images of this inflammation, which might help us understand how aneurysms grow. They will also check how consistent these scans are over time. You can join if you are at least 18 years old and have an AAA, or if you are a similar age and do not have an AAA (to serve as a comparison). The study aims to measure how much of the 64Cu-DOTA-ECL1i drug is taken up by the aorta, with measurements taken at 3 months.
- Study design
- This is an observational study with a planned enrollment of 30 participants. It is not specified if the study is randomized or blinded.
- What's involved
- Participants will undergo PET/CT scans with the 64Cu-DOTA-ECL1i drug at baseline and again approximately 6-8 weeks later.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary endpoint measurement for drug uptake is at 3 months.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Molecular Imaging of the Underlying Mechanism of Vessel Wall Inflammation Using Positron Emission Tomography (PET/CT)
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Scott M Damrauer, MD · PRINCIPAL_INVESTIGATOR · Penn Medicine Division of Vascular Surgery
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- • Measure uptake of 64Cu-DOTA-ECL13 months
• Measure uptake of 64Cu-DOTA-ECL1i in patients with abdominal aortic aneurysm at two time points to evaluate intra-individual variability of radiotracer uptake